Keywords: rituxan, revenues, boost, genentech, 2nd, quarter, biotechnology
Rituxan Revenues Boost Genentech's 2nd Quarter
Article | 14 July 1998
US biotechnology firm Genentech Inc reports a 70% increase insecond-quarter 1998 net income at $40.4 million, or 32 cents per share. This increase, the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
